1. Home
  2. HHH vs MIRM Comparison

HHH vs MIRM Comparison

Compare HHH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Howard Hughes Holdings Inc.

HHH

Howard Hughes Holdings Inc.

HOLD

Current Price

$80.34

Market Cap

5.0B

Sector

Real Estate

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$79.85

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HHH
MIRM
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
HHH
MIRM
Price
$80.34
$79.85
Analyst Decision
Buy
Strong Buy
Analyst Count
2
11
Target Price
$90.00
$92.45
AVG Volume (30 Days)
394.3K
809.5K
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
234.52
N/A
EPS
5.10
N/A
Revenue
$1,834,033,000.00
$471,794,000.00
Revenue This Year
N/A
$53.78
Revenue Next Year
$19.38
$19.91
P/E Ratio
$15.73
N/A
Revenue Growth
69.81
53.66
52 Week Low
$61.41
$36.88
52 Week High
$91.07
$82.58

Technical Indicators

Market Signals
Indicator
HHH
MIRM
Relative Strength Index (RSI) 41.18 63.35
Support Level $77.47 $77.99
Resistance Level $80.86 $82.58
Average True Range (ATR) 1.84 3.21
MACD -0.40 1.07
Stochastic Oscillator 28.07 86.72

Price Performance

Historical Comparison
HHH
MIRM

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: